Abstract: An object is to provide an epoxy resin composition which exhibits excellent tracking resistance and additionally has excellent heat resistance with a Tg of 200° C. or higher and flame retardancy. Provided is an epoxy resin composition which contains a phosphorus-containing epoxy resin and a curing agent and has a phosphorus content of within a range of 1.0 to 1.8%, wherein the phosphorus-containing epoxy resin has a ratio (L/H) of 0.6 to 4.0 of the content of trinuclear bodies (L) to the content of hepta or higher nuclear bodies (H) measured by GPC, and is a product obtained from a novolac epoxy resin having an average number of functional groups (Mn/E) of 3.8 to 4.8 and a phosphorus compound represented by the following general formula (1) and/or general formula (2).

Abstract: [Problem] To provide an ultrasonic apparatus that enables one to find a factor that lowers reliability of a measurement value relating to elasticity of biological tissue. [Means for Solution] An ultrasonic diagnostic apparatus comprises a control circuit executing: a measurement-value calculating function 535 of calculating a measurement value relating to elasticity of the biological tissue based on echo signals from ultrasonic detecting pulses; an index-value calculating function 536 of calculating an index value indicating a degree of reliability for the measurement value for each of a plurality of factors that deteriorate the reliability of the measurement value based on the echo signals from the ultrasonic detecting pulses; and a notifying function of notifying a factor corresponding to at least one index value for which the degree of reliability does not meet a required standard.

Abstract: A system 100 comprises a first medical image capture apparatus UL1 and a second medical image capture apparatus UL2 that share values of at least some of a plurality of preferences and are of different kinds, wherein a first control device 81 in the first ultrasonic diagnostic apparatus UL1 executes an output function of outputting a value of a preference that the first input device 71 has accepted, to a server 104 along with information on the kind of the first ultrasonic diagnostic apparatus UL1, and a server control device 1411 converts the output value of the preference based on conversion information, and then, transmits the converted value to the second ultrasonic diagnostic apparatus UL2. The second ultrasonic diagnostic apparatus UL2 converts the converted value from the server 104 into that in the kind of the second medical image capture apparatus, and performs setting of the converted value.

Abstract: An object is to provide an epoxy resin composition which exhibits excellent tracking resistance and additionally has excellent heat resistance with a Tg of 200° C. or higher and flame retardancy. Provided is an epoxy resin composition which contains a phosphorus-containing epoxy resin and a curing agent and has a phosphorus content of within a range of 1.0 to 1.8%, wherein the phosphorus-containing epoxy resin has a ratio (L/H) of 0.6 to 4.0 of the content of trinuclear bodies (L) to the content of hepta or higher nuclear bodies (H) measured by GPC, and is a product obtained from a novolac epoxy resin having an average number of functional groups (Mn/E) of 3.8 to 4.8 and a phosphorus compound represented by the following general formula (1) and/or general formula (2).

Abstract: A system comprises a plurality of ultrasonic diagnostic apparatuses connected via a network, and comprises: a storage device in which specification information for specifying some of preferences A, B, C to be shared between first and second ultrasonic diagnostic apparatuses is stored; and at least one control device. The control device executes a deciding function of deciding, once the first ultrasonic diagnostic apparatus has accepted an input of a value of at least any one of the plurality of preferences A, B, C, whether or not a preference corresponding to the input value is the preference to be shared based on said specification information, and sets the value of the preference into the second ultrasonic diagnostic apparatus.

Abstract: [Problem] To provide an ultrasonic apparatus that enables one to find a factor that lowers reliability of a measurement value relating to elasticity of biological tissue. [Means for Solution] An ultrasonic diagnostic apparatus comprises a control circuit executing: a measurement-value calculating function 535 of calculating a measurement value relating to elasticity of the biological tissue based on echo signals from ultrasonic detecting pulses; an index-value calculating function 536 of calculating an index value indicating a degree of reliability for the measurement value for each of a plurality of factors that deteriorate the reliability of the measurement value based on the echo signals from the ultrasonic detecting pulses; and a notifying function of notifying a factor corresponding to at least one index value for which the degree of reliability does not meet a required standard.

Abstract: A system 100 comprises a first medical image capture apparatus UL1 and a second medical image capture apparatus UL2 that share values of at least some of a plurality of preferences and are of different kinds, wherein a first control device 81 in the first ultrasonic diagnostic apparatus UL1 executes an output function of outputting a value of a preference that the first input device 71 has accepted, to a server 104 along with information on the kind of the first ultrasonic diagnostic apparatus UL1, and a server control device 1411 converts the output value of the preference based on conversion information, and then, transmits the converted value to the second ultrasonic diagnostic apparatus UL2. The second ultrasonic diagnostic apparatus UL2 converts the converted value from the server 104 into that in the kind of the second medical image capture apparatus, and performs setting of the converted value.

Abstract: A system comprises a plurality of ultrasonic diagnostic apparatuses connected via a network, and comprises: a storage device in which specification information for specifying some of preferences A, B, C to be shared between first and second ultrasonic diagnostic apparatuses is stored; and at least one control device. The control device executes a deciding function of deciding, once the first ultrasonic diagnostic apparatus has accepted an input of a value of at least any one of the plurality of preferences A, B, C, whether or not a preference corresponding to the input value is the preference to be shared based on said specification information, and sets the value of the preference into the second ultrasonic diagnostic apparatus.

Abstract: The present invention relates to a process for synthesizing or amplifying efficiently a nucleic acid comprising a target nucleic acid sequence. In the process according to the present invention, a primer comprising in its 3?-end portion a sequence (Ac?) which hybridizes a sequence (A) in the 3?-end portion of the target nucleic acid sequence, and in the 5?-side of said sequence (Ac?) a sequence (B?) which hybridizes the complementary sequence (Bc) of a sequence (B) positioned in the 5?-side of said sequence (A) on the target nucleic acid sequence, wherein {X?(Y?Y?)}/X is in the range of ?1.00 to 1.00, in which X denotes the number of bases in said sequence (Ac?), Y denotes the number of bases in the region flanked by said sequences (A) and (B) in the target nucleic acid sequence, and Y? denotes the number of bases in an intervening sequence between said sequences (Ac?) and (B?) (Y? may be zero).

Abstract: The present invention relates to a process for synthesizing or amplifying efficiently a nucleic acid comprising a target nucleic acid sequence. The process involves providing a primer comprising in its 3?-end portion a sequence (Ac?) which hybridizes a sequence (A) in the 3?-end portion of the target nucleic acid sequence, and in the 5?-side of the sequence (Ac?) a sequence (B?) which hybridizes the complementary sequence (Bc) of a sequence (B) positioned in the 5?-side of the sequence (A) on the target nucleic acid sequence, wherein {X?(Y?Y?)}/X is in the range of ?1.00 to 1.00, in which X denotes the number of bases in the sequence (Ac?), Y denotes the number of bases in the region flanked by the sequences (A) and (B) in the target nucleic acid sequence, and Y? denotes the number of bases in an intervening sequence between the sequences (Ac?) and (B?) (Y? may be zero).

Abstract: Means to circulate any nucleic acid molecule and to obtain from such circular nucleic acid molecules fragments that mark both ends of the initial nucleic acid molecule are provided. Means of high value to studies including, but not limited to, expression profiling, splicing, promoter identification, identification of genetic elements, and beyond, which are essential components of commercial applications and services including, but not limited to, drug development, diagnostics, or forensic studies are also provided.

Abstract: The invention is a method and a kit for preparing single-stranded DNA from double-stranded DNA and the purification of single-stranded DNA derived from double-stranded DNA. A single-stranded-DNA binding substance is used in combination with a double-strand-specific endonuclease for the removal of undesired double-stranded DNA from a single-stranded DNA preparation and for other related purposes.

Abstract: The present invention provides a method for identifying, analyzing and/or cloning nucleic acid isoforms comprising the steps of: preparing at least two nucleic acid isoforms, complementary to each other, hybridizing the at least two complementary nucleic acid isoforms and forming double strand RNA/RNA or DNA/DNA hybrids comprising unpaired regions; recovering the RNA/RNA or DNA/DNA hybrids comprising unpaired regions from not hybridized nucleic acids and from nucleic acids not comprising unpaired regions; and identifying, analyzing and/or cloning the recovered nucleic acid fragment comprising unpaired regions.

Abstract: The present invention relates to a process for synthesizing or amplifying efficiently a nucleic acid comprising a target nucleic acid sequence. In the process according to the present invention, a primer comprising in its 3?-end portion a sequence (Ac?) which hybridizes a sequence (A) in the 3?-end portion of the target nucleic acid sequence, and in the 5?-side of said sequence (Ac?) a sequence (B?) which hybridizes the complementary sequence (Bc) of a sequence (B) positioned in the 5?-side of said sequence (A) on the target nucleic acid sequence, wherein {X?(Y?Y?)}/X is in the range of ?1.00 to 1.00, in which X denotes the number of bases in said sequence (Ac?), Y denotes the number of bases in the region flanked by said sequences (A) and (B) in the target nucleic acid sequence, and Y? denotes the number of bases in an intervening sequence between said sequences (Ac?) and (B?) (Y? may be zero).

Abstract: cDNA including the 5′-terminal sequence of full-length mRNA with a cap structure is synthesized from a mRNA sample containing the full-length mRNA with the cap structure and non-full-length mRNA without any cap structure in mixture. At the first step, the phosphate group at 5′-terminus of the non-full-length mRNA in the mRNA sample is removed. At the second step, the cap structure at the 5′-terminus of the full-length mRNA in the mRNA sample is removed. At the third step, an oligoribonucleotide is ligated to the phosphate group at 5′-terminus of mRNA generated through the first and second steps. At the fourth step, mRNA with the oligoribonucleotide ligated at the 5′-terminus thereof at the third step is subjected to a reverse transcriptase process using a short-chain oligonucleotide capable of being annealed to an intermediate sequence within the mRNA as primer, to synthesize a first-strand cDNA.

Abstract: This invention relates to a horseshoe crab amebocyte lysate factor G activation inhibitor comprising as an active ingredient a polyglycoside containing at least one poly-(1.fwdarw.3)-.beta.-D-glucoside structure portion consisting of 2 to 370 (1.fwdarw.3)-.beta.-D-glucoside structural units of the following formula ##STR1## which are continuously bound to one another. This inhibitor is useful for inhibiting the activation of factor G which may exist in horseshoe crab amebocyte lysate used in the Limulus test.

Abstract: The invention stabilizes single helix conformation (1.fwdarw.3)-.beta.-D-glucans by intramolecular crosslinking and provides (1.fwdarw.3)-.beta.-D-glucans showing stable biological activities. Thus, intramolecularly crosslinked (1.fwdarw.3)-.beta.-D-glucans having a stable single helix conformation are produced by introducing a functional group into hydroxyl groups of (1.fwdarw.3)-.beta.-D-glucans, then causing the thus-obtained functional glucans to take a single helix conformation, and subjecting these, either as such or after binding them to a receptor therefor, to intramolecular crosslinking between the functional groups introduced, if necessary followed by releasing the receptor therefrom.

Abstract: This invention relates to a horseshoe crab amebocyte lysate factor G activation inhibitor comprising as an active ingredient a polyglycoside containing at least one poly-(1.fwdarw.3)-.beta.-D-glucoside structure portion consisting of 2 to 370 (1.fwdarw.3)-.beta.-D-glucoside structural units of the following formula ##STR1## which are continuously bound to one another. This inhibitor is useful for inhibiting the activation of factor G which may exist in horseshoe crab amebocyte lysate used in the Limulus test.

Abstract: Disclosed is a method of preparing limulus amoebocyte lysate substantially free from factor G which comprises bringing limulus amoebocyte lysate into contact with an insoluble carrier on which a (1.fwdarw.3)-.beta.-D-glucoside structural portion represented by the following formula [I] produced by depolymerizing and/or fractionating a carbohydrate chain is immobilized: ##STR1## wherein n represents an integer of 2 to 370.

Abstract: This invention relates to a horseshoe crab amebocyte lysate factor G activation inhibitor comprising as an active ingredient a polyglycoside containing at least one poly-(1.fwdarw.3)-.beta.-D-glucoside structure portion consisting of 2 to 370 (1.fwdarw.3)-.beta.-D-glucoside structural units of the following formula ##STR1## which are continuously bound to one another. This inhibitor is useful for inhibiting the activation of factor G which may exist in horseshoe crab amebocyte lysate used in the Limulus test.